No profit for Osprey Medical Inc but it's primed for growth

Growth investors still have their eyes on Osprey Medical Inc (ASX:OSP) despite a profit evading the company for another half.

| More on:
a woman

You鈥檙e reading a free article with opinions that may differ from The Motley Fool鈥檚 Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in medical device company, Osprey Medical Inc (ASX: OSP) opened up 1.6% to 30c per share today despite the company posting a net loss of $14.3 million on the release of its full year results for the year ended December 31 2017.

Osprey, with US-based operations, is focused on protecting patients from the harmful effects of contrast dye used during angiographic imaging, especially those with poor kidney function.

The full year net loss of $14.3 million has increased 22% from the prior corresponding period when a net loss of US$11.7 million was logged.

But Osprey has long caught the eye of growth investors, reporting full year sales revenue of US$1.6 million, up 178% from FY16 revenue of US$0.6 million, with proceeds of A$32.5 million from an oversubscribed capital raising completed in August 2017 and a 181% year-on-year growth in unit sales.

Operationally, Osprey announced its thirteenth consecutive quarter of sales growth for the final quarter of 2017, with strong lead indicators for future growth and 98 hospitals purchasing their DyeVert or DyeVert Plus products, with 62 hospitals in the evaluation-to-purchase phase.

Osprey Medical has seen significant share price volatility in the last 12 months, sliding from a January 19 high of 41c per share to 29c per share at month's end.

It is difficult to establish whether the loss-making Osprey has efficiently used shareholders' funds over the last year, but its higher-than-market average revenue increase is one of several figures heading in the right direction.

The company's debt-free balance sheet is also a bonus, with analysts expecting high earnings growth over the next few years for a small cap which appears to be positioned for growth.

Osprey is accelerating its product commercialisation, with a focus on podium presentations at leading industry events across the U.S. to strengthen its commercialisation strategy and it plans to have 35 sales force personnel to open new hospital accounts by the end of the 2018 calendar year.

Osprey's trading was impacted by U.S. hurricanes Harvey and Irma during the reporting period, but Osprey CEO Mike McCormick said the company returned to normal quickly afterwards with continued strong growth in unaffected territories.

In 2018 Osprey plan to initiate commercial pilot activities in several countries across Europe, with a European roll out planned for the 2019 calendar year.

A focus on physician awareness of dye reduction and monitoring will also underpin its market development strategy, with Osprey announcing proven customer adoption metrics in their December investor presentation and a 144% increase in new hospitals purchasing its products year on year.

Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on 鈴革笍 Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
鈴革笍 Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
鈴革笍 Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more

asx investor daydreaming about US shares
鈴革笍 How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more

鈴革笍 Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more